First GLP-1 analog liraglutide: the result of clinical trails on efficacy

First GLP-1 analog liraglutide: the result of clinical trails on efficacy

This review analytically considers the results of clinical trials on efficacy and safety and clinical perspectives of GLP-1 analog liraglutide

Saved in:

Bibliographic Details
Main Authors:	Alexander Sergeevich Ametov, Lyudmila Leonidovna Kamynina
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2011-12-01
Series:	Сахарный диабет
Subjects:	diabetes mellitus incretin glp-1 liraglutide
Online Access:	https://www.dia-endojournals.ru/jour/article/view/5815
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Liraglutide for the treatment of obesity
by: Elmien Bronkhorst, et al.
Published: (2016-05-01)

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01)

Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide
by: Zsombor I. Hegedűs, et al.
Published: (2025-06-01)

Liraglutide Attenuates Atorvastatin-Induced Hepatotoxicity by Restoring GLP-1R Expression and Activating Nrf2 and Autophagy Pathways in Wistar Rats
by: Engy A. Elsiad, et al.
Published: (2025-07-01)

Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD
by: Ahmad Moolla, et al.
Published: (2025-05-01)

The efficacy of liraglutide-based drugs on the model of induced metabolic syndrome in experimental animals
by: A. A. Andreev-Andrievsky, et al.
Published: (2025-08-01)

Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
by: Lyudmila Alexandrovna Ruyatkina, et al.
Published: (2017-06-01)

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review
by: Juliana West, et al.
Published: (2025-04-01)

Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis
by: Wang Shin Lei, et al.
Published: (2025-06-01)

Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study
by: Anders Boisen Jensen, et al.
Published: (2025-04-01)

Efficacy of GLP-1 analog to achieve metabolic control and correction of body weight in patients with type 2 diabetes mellitus
by: T. V. Saprina, et al.
Published: (2011-12-01)

Increase in circulating GLP-1 following low FODMAP diet in irritable bowel syndrome patients
by: Umael Khan, et al.
Published: (2025-08-01)

Dual melanocortin‐4 receptor and GLP‐1 receptor agonism amplifies metabolic benefits in diet‐induced obese mice
by: Christoffer Clemmensen, et al.
Published: (2015-02-01)

Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment
by: Łukasz Zdziebkowski, et al.
Published: (2025-07-01)

Russian development for drug independence in endocrinology: comparative analysis of bioequivalence, safety and tolerability of the first domestic liraglutide
by: A. S. Ametov, et al.
Published: (2023-11-01)

The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson’s disease with diabetes co-morbidity
by: Xiaomin Zhang, et al.
Published: (2025-06-01)

PANCREATIC AND EXTRA-PANCREATIC EFFECTS OF INCRETINS AND PERSPECTIVES FOR STUDYING ENTEROINSULIN HORMONAL SYSTEM DURING GESTATIONAL DISORDER OF CARBOHYDRATE METABOLISM
by: T. V. Saprina, et al.
Published: (2013-06-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Effect of high intakes of protein-only and carbohydrate-only on plasma metabolites and hormones, in addition to nitrogen excretion
by: Matthieu Clauss, et al.
Published: (2025-08-01)

Editorial: Incretin-based therapies in the treatment of metabolic syndrome: expanding roles beyond weight management
by: Kexin Zhang, et al.
Published: (2025-08-01)

Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis
by: Feng Wang, et al.
Published: (2025-07-01)

Features of the functional state of the enteropancreatic hormonal system in pregnant women with gestational diabetes mellitus
by: F. O. Ushanova, et al.
Published: (2023-12-01)

Patient-reported outcomes of glucagon-like peptide-1 agonists on hidradenitis suppurativa severity
by: Radhika Gupta, BA, et al.
Published: (2025-08-01)

Efficacy and Safety of Liraglutide in Adolescents Aged 12–15 Years with Obesity: a Prospective 24-week Observational
by: Olga P. Kovtun, et al.
Published: (2025-05-01)

The effect of liraglutide on metabolic and reproductive outcomes in infertile women with PCOS: A prospective cohort study
by: Rossella Cannarella, et al.
Published: (2025-09-01)

Effect of GLP-1 Receptor Agonists (Liraglutide) on Glycemic Parameters and Circulating miRNA Expression in Type 2 Diabetes Mellitus
by: Aqeel Meer AL-ZAMILY
Published: (2025-06-01)

Beneficial effects of liraglutide on peripheral blood vessels
by: Zhang Xueyang, et al.
Published: (2022-01-01)

Could Increased Glp1r Expression via Sitagliptin in the GLP-1/GLP-1 Receptor Axis in the DietInduced Obesity Rat Model be Important in Liver Metabolism?
by: Cem Horozoğlu, et al.
Published: (2024-12-01)

Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity
by: Vladimir Ivanovich Kudinov, et al.
Published: (2011-06-01)

Revisiting the role of novel weight management medications and bariatric surgery
by: LIANG Hui
Published: (2025-06-01)

Effects of liraglutide on 8-OHdG,MDA and SOD of kidney in insulin resistance rats
by: WU Ming-hao, et al.
Published: (2017-01-01)

Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies
by: Vincenzo Trapanese, et al.
Published: (2025-05-01)

Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
by: Lívia C. R. Teixeira, et al.
Published: (2025-01-01)

Regulating effect of empagliflozin plus liraglutide on glucose/lipid metabolism and serum levels of SFRP5， Irisin and tAPN in obese type 2 diabetics
by: Gao Rui-chao, et al.
Published: (2022-07-01)

LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST
by: S. V. Nedogoda
Published: (2018-05-01)

Role of incretin based therapies in the treatment of diabetic kidney disease
by: Paola Fioretto, et al.
Published: (2018-11-01)

GLP-1/GLP-1R axis: from metabolism (obesity and T2DM) to immunity
by: Vijay Kumar
Published: (2025-07-01)

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01)

Knowledge, attitude and practice toward liraglutide and semaglutide among endocrinology medical staff
by: Bingling Liu, et al.
Published: (2025-04-01)

Liraglutide use in pediatric type 2 familial partial lipodystrophy caused by LMNA mutation: a case report
by: Youran Li, et al.
Published: (2025-07-01)